Venous thromboembolism
Jun 1, 2025, 03:33
Blood Advances Study Reveals Misclassification of Venous Thromboembolism (VTE) Risk
American Society of Hematology shared a post on X:
“Venous thromboembolism (VTE) affects 1 million Americans yearly. A recent study in Blood Advances shows 1 in 3 medical patients had misclassified VTE risk, leading to inappropriate treatment for half. ”
Accurate VTE risk assessment is essential to avoid both under- and overtreatment. This study draws attention to how often patients are misclassified.
Check out the full study here.
Get the latest news on Hemostasis Today.
-
Jun 9, 2026, 08:54Shujha Abbas: Understanding the Real Cost of Gene Therapie
-
Jun 9, 2026, 04:47Akshat Jain: Marstacimab Gets FDA Expension for Children with Hemophilia B
-
Jun 9, 2026, 03:30Fayad Al-Haimus: High-Risk Emergencies and Lifelong Learning at CAEP 2026
-
Jun 9, 2026, 03:14Rucha Patil: A Collaborative Initiative to Transform Rare Blood Disorder Care in Rajasthan
-
Jun 9, 2026, 02:28Andreas Calatzis: Chasing Biologically Inactive Heparin?
-
Jun 9, 2026, 02:16Javier Lagos Servellon: Reflections on Completing the University of Bern’s Stroke Medicine Program
-
Jun 8, 2026, 17:50From Bleeding to Swelling – A Shared Therapeutic Revolution in Rare Diseases – RPTH Journal
-
Jun 8, 2026, 17:36Sophia Delicou: Decoding Acute Pain Transfusion Reactions in Thalassemia
-
Jun 8, 2026, 16:21Ifeanyichukwu Ifechidere: Reflections on the UK NEQAS Coagulation and Haemostasis Conference